Cogent Biosciences
COGT
148 hedge funds and large institutions have $1.02B invested in Cogent Biosciences in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 54 increasing their positions, 47 reducing their positions, and 23 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
39% more capital invested
Capital invested by funds: $734M → $1.02B (+$289M)
21.81% more ownership
Funds ownership: 105.14% → 126.96% (+22%)
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
15% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 47
1% more funds holding
Funds holding: 146 → 148 (+2)
12% less call options, than puts
Call options by funds: $1.68M | Put options by funds: $1.91M
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.8M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$27.5M |
| 3 |
CC
Commodore Capital
New York
|
+$25.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.1M |
| 5 |
DM
Deerfield Management
New York
|
+$16.8M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$28.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$15.8M |
| 3 |
Millennium Management
New York
|
-$8.53M |
| 4 |
Morgan Stanley
New York
|
-$6.59M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.94M |
COGT Hedge Fund Activity: Q2 2024 in Review
148 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2024, worth a combined $1.02B — up 39% from $734M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new COGT positions and 23 closed out — a net gain of 5 holders — while 54 added to existing stakes and 47 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $28.8M. The largest seller was State Street, cutting an estimated $28.7M.
- 148 institutional investors held Cogent Biosciences (COGT) as of Q2 2024, up from 146 in Q1 2024.
- Funds reported $1.02B of Cogent Biosciences stock for Q2 2024, up 39% quarter-over-quarter.
- 28 funds opened new Cogent Biosciences positions in Q2 2024 and 23 closed out, a net change of +5 holders.
- The largest Cogent Biosciences buyer in Q2 2024 was Point72 Asset Management, an estimated $28.8M added.
- The largest Cogent Biosciences seller in Q2 2024 was State Street, an estimated $28.7M sold.
Based on aggregated 13F filings for Q2 2024.